Skip to main content

Table 1 Baseline characteristics of patients switching from premix to glargine

From: Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary care-based analysis

  Type 1 diabetes Type 2 diabetes
n (%) 183 (35) 345 (65)
% male 53.0 53.0
Age (years)* 22.9 ± 15.5 55.8 ± 16.6
Weight (kg)* 67.7 ± 2.7 85.3 ± 2.2
Baseline HbA1c *† 9.4 ± 1.6 9.3 ± 1.5
Duration of diabetes (years)‡ 7.9 ± 8.7 8.1 ± 6.7
Number of co-morbidities§ 2.5 ± 2.4 2.4 ± 1.9
Premix insulin only (%) 61% 48%
Premix insulin with OAD (%) 0% 38%
Premix + short acting insulin (%) 25% 16%
Premix + basal insulin (%) 8% 5%
Premix + short acting + basal insulin (%) 2% 3%
Premix + other insulin +/-OADs (%) 0% 2%
OADs per patient before starting insulin therapy*¶ - 0.4 ± 0.5
Hypoglycaemia episodes in 3 month period*||   
   No. episodes 38 72
   Mean no. episodes per patient 0.21 0.21
  1. OAD = oral antidiabetic drug; HbA1c = glycated haemoglobin. Data are mean ± SD unless indicated.
  2. *Significant variables investigated in multivariate analysis.
  3. †Data missing for 29 patients with type 1 diabetes and 27 patients with type 2 diabetes.
  4. ‡Data missing for 2 patients with type 1 diabetes and 5 patients with type 2 diabetes.
  5. §Includes myocardial infarction, stroke, peripheral vascular disease, neuropathy, nephropathy and retinopathy.
  6. ¶Number of oral diabetic treatments (e.g. metformin, sulfonylureas) prescribed prior to commencing insulin.
  7. ||Hypoglycaemic episodes reported during the 3 month period prior to switch. Episodes reported in 27 patients with type 1 diabetes and 44 patients with type 2 diabetes.